Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VRNA 
Verona Pharma PLC ADR (VRNA)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2025: VRNA (5-star) is a STRONG-BUY. BUY since 99 days. Simulated Profits (45.12%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $106.22
1 Year Target Price $106.22
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 397.54% | Avg. Invested days 78 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/18/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.03B USD | Price to earnings Ratio - | 1Y Target Price 106.22 |
Price to earnings Ratio - | 1Y Target Price 106.22 | ||
Volume (30-day avg) 10 | Beta 0.14 | 52 Weeks Range 27.54 - 106.45 | Updated Date 09/18/2025 |
52 Weeks Range 27.54 - 106.45 | Updated Date 09/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -36.63% | Operating Margin (TTM) 12.9% |
Management Effectiveness
Return on Assets (TTM) -6.68% | Return on Equity (TTM) -36.36% |
Valuation
Trailing PE - | Forward PE 34.72 | Enterprise Value 9000003278 | Price to Sales(TTM) 40.75 |
Enterprise Value 9000003278 | Price to Sales(TTM) 40.75 | ||
Enterprise Value to Revenue 40.6 | Enterprise Value to EBITDA -20.89 | Shares Outstanding 84978881 | Shares Floating 564820417 |
Shares Outstanding 84978881 | Shares Floating 564820417 | ||
Percent Insiders 4.89 | Percent Institutions 95.89 |
Upturn AI SWOT
Verona Pharma PLC ADR
Company Overview
History and Background
Verona Pharma PLC ADR (VRNA) is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. Founded in 2006, it has focused on developing ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory indications.
Core Business Areas
- Respiratory Drug Development: Focuses on developing and commercializing therapies for respiratory diseases, primarily COPD, asthma, and cystic fibrosis.
- Ensifentrine: Development and potential commercialization of ensifentrine, a novel dual PDE3/4 inhibitor, for COPD and other respiratory diseases.
Leadership and Structure
Dr. David Zaccardelli is the CEO. The company has a Board of Directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- Ensifentrine: A first-in-class, inhaled dual PDE3 and PDE4 inhibitor being developed for COPD and other respiratory diseases. If approved, it will compete with existing bronchodilators and inhaled corticosteroids. Anticipated competitors: GSK(TRELEGY ELLIPTA), Boehringer Ingelheim(SPIRIVA), AstraZeneca(SYMBICORT). No current market share, pending FDA approval. EvaluatePharma consensus peak sales est. $1.1 billion
Market Dynamics
Industry Overview
The respiratory disease market is large and growing, driven by aging populations, pollution, and smoking. COPD and asthma are major segments with significant unmet needs.
Positioning
Verona Pharma is positioned as an innovator with its novel dual PDE3/4 inhibitor. Its competitive advantage lies in the potential for ensifentrine to improve lung function and reduce exacerbations in COPD patients.
Total Addressable Market (TAM)
The COPD market is estimated to be ~$40 billion. Verona Pharma is positioned to capture a portion of this TAM with ensifentrine, pending regulatory approval and successful commercialization.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (dual PDE3/4 inhibition)
- Positive Phase 3 clinical trial results for ensifentrine in COPD
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Dependence on the success of ensifentrine
- Lack of established commercial infrastructure
- Limited financial resources compared to larger pharmaceutical companies
- Regulatory approval risk
Opportunities
- Potential approval and commercialization of ensifentrine in COPD
- Expansion of ensifentrine into other respiratory indications (asthma, cystic fibrosis)
- Partnerships with larger pharmaceutical companies
- Growing prevalence of COPD and other respiratory diseases
Threats
- Competition from existing COPD therapies
- Failure to obtain regulatory approval for ensifentrine
- Adverse events or safety concerns related to ensifentrine
- Generic erosion of existing COPD therapies
Competitors and Market Share
Key Competitors
- GSK (GSK)
- AstraZeneca (AZN)
- Boehringer Ingelheim (Private)
- Novartis (NVS)
Competitive Landscape
Verona Pharma is a smaller player competing with larger pharmaceutical companies. Its advantage lies in its novel mechanism of action and strong clinical trial data, but it faces challenges in terms of commercialization and marketing.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in stock price appreciation based on clinical trial results.
Future Projections: Future growth is heavily dependent on the approval and commercial success of ensifentrine. Analyst estimates vary, but project significant revenue growth if approved.
Recent Initiatives: Focus on obtaining regulatory approval for ensifentrine and preparing for commercial launch. Exploring potential partnerships.
Summary
Verona Pharma is a clinical-stage biopharmaceutical company heavily reliant on the success of ensifentrine. Positive Phase 3 trial results offer promise, but regulatory approval and effective commercialization are crucial. The company faces competition from established players in the COPD market and requires significant capital to execute its strategy. Verona Pharma's success hinges on its potential to provide a differentiated therapeutic option with its dual PDE3/4 inhibitor.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Press Releases
- Analyst Reports
- EvaluatePharma
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share estimates are approximate and may vary. Future results are not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Verona Pharma PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-04-27 | President, CEO & Executive Director Dr. David Scott Zaccardelli Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 209 | Website https://www.veronapharma.com |
Full time employees 209 | Website https://www.veronapharma.com | ||
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.